Overall survival with neoadjuvant nivolumab (NIVO) + chemotherapy (chemo) in patients with resectable NSCLC in CheckMate 816 Meeting Abstract
| Authors: | Forde, P. M.; Spicer, J.; Provencio, M.; Mitsudomi, T.; Awad, M. M.; Wang, C.; Lu, S.; Felip, E.; Broderick, S.; Swanson, S.; Brahmer, J. R.; Kerr, K.; Ciuleanu, T. E.; Tanaka, F.; Saylors, G. B.; Chen, K.; Wang, L.; Duong, Q.; Girard, N. |
| Abstract Title: | Overall survival with neoadjuvant nivolumab (NIVO) + chemotherapy (chemo) in patients with resectable NSCLC in CheckMate 816 |
| Meeting Title: | 2025 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 43 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2025 May 30-Jun 3 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2025-06-01 |
| DOI: | 10.1200/JCO.2025.43.17_suppl.LBA8000 |
| PROVIDER: | EBSCOhost |
| PROVIDER: | cinahl |
| DOI/URL: | |
| Notes: | Meeting Abstract: LBA8000 -- Source: Cinahl |
